NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019

By April 30, 2019

Management to discuss new partner pharmacy program and expanded access to in-office direct channel

EMERYVILLE, Calif. (April 30, 2019)NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report first quarter 2019 financial results after market close on Thursday, May 9, 2019 and will hold an investment community conference call that day.

In addition to discussing financial results during the call, management will provide updates on recent initiatives to increase sales while decreasing costs. The sales initiatives entail improved patient accessibility to Avenova through an expanded partner pharmacy program and increased outreach efforts to eye care specialists to sell Avenova directly to their patients through its in-office direct channel. Management will also provide an update on previously announced cost-containment measures to align expenses with the recent strategic shift in its commercialization strategy.

DATE: Thursday, May 9
TIME: 4:30 p.m. ET / 1:30 p.m. PT
DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 8495204

The live call also will be available at A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Pacific time May 17, 2019, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 8495204. The call will also be archived at

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For NovaBay Avenova purchasing information:
Please Call us toll free: 1-800-890-0329 or email

NovaBay Contact
Justin Hall
Interim President and Chief Executive Officer

Investor Contact
Jody Cain